ABSTRACT
Abbreviations used
AD: Atopic dermatitis AHR: Airway hyperresponsiveness APC: Allophycocyanin BALF: Bronchoalveolar lavage fluid DC: Dendritic cell ILC: Innate lymphoid cell ILC1: Type 1 innate lymphoid cell OVA: Ovalbumin TCR: T-cell receptor WT: Wild-type depending on age of onset, severity or persistence of disease, allergic status, or response to treatment modalities. Despite decades of research, knowledge of the cellular and molecular mechanisms in asthmatic patients remains incomplete, constituting a barrier for optimal management of patients with the disease.
Atopic dermatitis (AD) often precedes asthma, a phenomenon known as the atopic march. 2 AD is a common allergic skin inflammatory disease that often starts in infancy and affects more than 17% of children in the Unites States. Acute AD skin lesions are characterized by epidermal and dermal thickening and by dermal infiltration of CD4
1 T cells and eosinophils, predominant expression of the T H 2 cytokines IL-4 and IL-13, and increased expression of IL-22 and IL-17A. [3] [4] [5] The roles of T H 2 cytokines and IL-17A have been studied extensively in mouse models of the atopic march. [6] [7] [8] [9] [10] However, little is known about the role of IL-22 in this disease progression.
IL-22 is a member of the IL-10 family of cytokines produced by adaptive T H 17 and T H 22 cells, innate lymphocytes that include gd T cells and type 3 innate lymphoid cells (ILCs), as well as myeloid cells, including neutrophils. [11] [12] [13] [14] [15] The IL-22 receptor is expressed on epithelial cells, but not immune cells, 16 indicating an important role for IL-22 signaling in mucosal barrier function. Increased IL-22 levels have been observed in lungs, bronchoalveolar lavage fluid (BALF), and sera of asthmatic patients. [17] [18] [19] Increased lung IL-22 levels have been observed in mouse models of asthma on airway challenge. 17, [20] [21] [22] IL-22 inhibits expression of proinflammatory chemokines and adhesion molecules induced by IFN-g in human bronchial epithelial cells, 23 suggesting that it could play a protective role in asthmatic patients. In contrast, IL-22 enhances the proliferation and migration of human airway smooth muscle cells, 24, 25 suggesting that it could play a pathogenic role in asthma. Genetic deletion of Il22 in mice or administration of IL-22-blocking antibody to wild-type (WT) mice aggravates the airway inflammation and airway hyperresponsiveness (AHR) elicited by intranasal challenge of intraperitoneally immunized mice. 17, 21, 22 Reciprocally, intranasal instillation of rIL-22 before intranasal challenge of intraperitoneally sensitized mice reduced airway inflammation and AHR, 17, 21 suggesting a protective role of IL-22. In contrast, genetic deletion of Il22 in mice or administration of IL-22-blocking antibody to WT mice reduced airway inflammation in mice sensitized subcutaneously with ovalbumin (OVA). 17 Thus IL-22 appears to play opposing roles in antigen-driven mouse models of asthma, depending on the route of immunization.
Neither intraperitoneal nor subcutaneous immunization mimic antigen sensitization in patients. We have previously reported that mice sensitized epicutaneously by means of application of antigen to tape-stripped skin, which mimics antigen cutaneous exposure to antigen in patients with AD, have allergic skin inflammation with features of AD. 26 Antigen challenge of epicutaneously sensitized mice results in airway inflammation and AHR with features of allergic asthma. 26 This model mimics the atopic march in patients with AD who have asthma driven by antigens that had been initially introduced through a disrupted skin barrier.
Here we demonstrate a role for IL-22 in airway inflammation and AHR in this model, suggesting that IL-22 might play a role in asthma that develops during the atopic march in patients with AD.
METHODS

Mice and sensitization
Il22
2/2 mice were described previously. 27 WT BALB/c and DO11.10 Tcell receptor (TCR)-transgenic mice were obtained from Charles River Laboratories (Wilmington, Mass) and the Jackson Laboratory (Bar Harbor, Me), respectively. All mice were housed in a specific pathogen-free environment and fed an OVA-free diet. Epicutaneous and intraperitoneal sensitization of 6-to 10-week-old mice was done, as previously described. 7 All procedures were performed in accordance with the Animal Care and Use Committee of Boston Children's Hospital.
RNA extraction and quantitative PCR analysis
RNA was extracted from whole lungs with the Total RNA Isolation Kit (Ambion, Foster City, Calif). cDNA was prepared with the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, Calif). Quantitative real-time PCR was done with TaqMan gene expression assays, universal PCR Master Mix, and ABI Prism 7300 sequence detection system (Applied Biosystems, Foster City, Calif).
Cytokine production by spleen and lung cells
Spleen and lung single-cell suspensions were cultured at 4 3 10 6 /mL in the presence of OVA (200 mg/mL) for 96 hours, as described previously. 28 Cytokine levels in supernatants were measured by means of ELISA with ReadySet-Go! ELISA Kits (eBioscience, San Diego, Calif), according to the manufacturer's instructions.
Intranasal treatment and analysis of airway inflammation and AHR
Intranasal challenge with OVA (50 mg) was performed daily for 3 days, followed by analysis of airway hyperreactivity responses. Lung resistance was measured with invasive Buxco (Buxco Electronics, Wilmington, NC) in response to increasing doses of methacholine administered by means of nebulization to anesthetized mice 24 hours after the last intranasal treatment. Immediately after death, BALF was collected, total cells were counted, and numbers of leukocytes was determined from cytospin preparations stained with the Diff-Quik Stain Set (Baxter, Miami, Fla).
Recombinant mouse cytokines were purchased from R&D Systems (Minneapolis, Minn). Mice were treated with mouse rIL-22 (100 or 1000 ng), rTNF-a (50 ng), rIL-17A (100 ng), and rIL-13 (500, 1000, or 2500 ng) alone or in combination for 3 consecutive days. For IFN-g-blocking experiments, mice were treated with 50 mg of mAb against IFN-g (clone XMG1.2; Bio X Cell, West Lebanon, NH), 15 mg of mAb against IL-22 or TNF (R&D Systems), or isotype control (Bio X Cell or R&D Systems) during intranasal OVA challenge.
Histologic analysis
Lung specimens were fixed in 4% paraformaldehyde and embedded in paraffin. Hematoxylin and eosin staining was performed in 5-mm sections.
Antibodies and flow cytometry
Lung cells were incubated with an anti-FcgRIII/II antibody (eBioscience) on ice for 15 minutes to block Fc receptors, washed, and incubated with eF506 viability dye (eBioscience), allophycocyanin (APC)-Cy7-conjugated anti-GR1 (RB6-8C5; eBioscience), fluorescein isothiocyanate-conjugated antiCD11b (M1/70; BioLegend, San Diego, Calif), eFluor-450-anti-CD3 (17A2; eBioscience), APC-anti-CD4 (GK1.5; eBioscience), APC-Cy7-conjugated anti-CD90 (53-2.1; eBioscience), phycoerythrin-anti-CD8 (53-6.7; eBioscience), and peridinin-chlorophyll-protein complex-eF710-conjugated TCR gd (eBioGL3; eBioscience) for 15 minutes. For ILC staining, biotinanti-CD11b (M1/70), biotin-anti-CD11c (N418), biotin-anti-F4-80 (BM8), biotin-anti-B220 (RA3-6B2), biotin-anti-CD19 (1D3), biotin-anti-FcεRIa (MAR-1), biotin-anti-CD49b (DX5), and biotin-anti-Gr1 (RB6-8C5) from eBioscience, followed by Streptavidin-BV605 (BD, Franklin Lakes, NJ), were use as lineage gate. ILCs were defined as CD45 
T H 22 in vitro polarization and adoptive transfer
Naive CD4 1 T cells from DO11.10 transgenic mice were isolated from spleens by using the Naive CD41 T Cell Isolation Kit, Mouse (Miltenyi Biotec, Bergisch Gladbach, Germany). Naive cells (1 3 10 6 ) were cultured for 4 days in anti-CD3 antibody-coated wells (2 mg/mL) with anti-CD28 antibody (2 mg/mL), IL-6 (50 ng/mL), IL-23 (50 ng/mL), anti-IL-4 antibody (10 mg/ mL), anti-IFN-g antibody (10 mg/mL), and anti-TGF-b antibody (10 mg/ mL). Then 2 3 10 6 T H 22 in vitro-polarized cells were injected intravenously in WT mice. (Fig 1, A) and IL-22 serum levels (Fig 1, B) . C and D, Il22 mRNA expression in the lungs (Fig 1, C) and IL-22 secretion by OVAstimulated lung cells (Fig 1, D) . E, Representative fluorescence-activated cell sorting analysis and quantitation of intracellular expression of Fig   1 , A and B, followed by intranasal challenge with OVA in Fig 1, C-F. Bars represent means 6 SEMs (n 5 5-10 per group). *P < .05 and **P < .005.
Statistical analysis
Results were analyzed by using 2-way ANOVA or nonparametric t tests. A P value of less than .05 was considered significant.
RESULTS
Epicutaneous sensitization elicits a systemic IL-22 response and an antigen-specific IL-22 response in the lungs Previously, we demonstrated that epicutaneous sensitization through application of antigen to tape-stripped mouse skin promotes systemic type 2 and type 17 immune responses. 7, 29 We examined whether epicutaneous sensitization also elicits a systemic IL-22 response. Splenic cells from mice sensitized epicutaneously with OVA secreted significantly more IL-22 when cultured in vitro with OVA compared with splenic cells from control mice sensitized epicutaneously with saline (Fig 1, A) . Furthermore, as we previously described, epicutaneous sensitization with OVA, but not saline, resulted in a significant increase in serum IL-22 levels (Fig 1, B) . These findings demonstrate that epicutaneous sensitization with antigen elicits a systemic IL-22 response.
We next investigated whether intranasal OVA challenge of mice sensitized epicutaneously with OVA causes Il22 mRNA expression and IL-22 production in the lungs. After intranasal OVA challenge, Il22 mRNA levels in the lungs were significantly increased in mice sensitized epicutaneously with OVA compared with control mice sensitized epicutaneously with saline (Fig 1, C) . In addition, lungs cells from mice sensitized epicutaneously with OVA secreted significantly higher amounts of IL-22 in response to OVA restimulation in vitro compared with lung cells from control mice sensitized epicutaneously with saline (Fig 1, D) . These results demonstrate that epicutaneous sensitization elicits an antigen-specific IL-22 response in response to airway antigen challenge.
Lung cell suspensions were analyzed by using flow cytometry to identify cellular sources of IL-22 in the lungs of mice that were challenged intranasally and sensitized epicutaneously. Fluorescence-activated cell sorting showed significantly increased percentages of CD3
IL-22
1 cells in the lungs of mice sensitized epicutaneously with OVA compared with mice sensitized epicutaneously with saline (Fig 1, E) . These CD3
1
CD4
1 IL-22 1 cells coexpressed the cytokines TNF-a (90% 6 5%, n 5 4) and IL-17A (50% 6 8.4% n 5 4). IL-22 expression was barely detected or not detected in CD3 Epicutaneous sensitization preferentially promotes an IL-22 response IL-22 serum levels (Fig 2, A) , IL-22 and TNF-a secretion by splenocytes stimulated with OVA in vitro (Fig 2, B Tnfa mRNA expression in the lungs after OVA airway challenge (Fig 2, C) , and IL-22 and TNF-a secretion in response to OVA stimulation by lung cells from airway-challenged mice (Fig 2,  D) were all significantly less in mice immunized intraperitoneally with OVA compared with mice sensitized epicutaneously with OVA. As previously reported, 7 IL-17A production by OVAstimulated splenocytes was greater in mice sensitized epicutaneously than in mice immunized intraperitoneally, whereas IL-4, IL-13, and IFN-g production and serum OVA-specific IgE levels were comparable between the 2 groups (data not shown). These results show that epicutaneous sensitization preferentially promotes a systemic IL-22 response and, importantly, production of IL-22 and TNF-a in the lungs after intranasal challenge.
Previously, we had shown that TGF-b, which is richly expressed in the skin, is important for inducing an IL-17A response to epicutaneous sensitization with OVA. 7 To examine whether TGF-b plays a role in the IL-22 response to epicutaneous sensitization, we injected a neutralizing antibody to TGF-b 6 hours before epicutaneous sensitization and then examined dendritic cells (DCs) isolated from draining lymph nodes 24 hours after epicutaneous sensitization for their ability to drive cytokine production by naive OVA-TCR transgenic DO11.10 T cells. TGFb blockade had no effect on the ability of DCs to drive IL-22 production by naive T cells (see Fig E2 in this article's Online Repository at www.jacionline.org). However, as we reported previously, 7 it significantly impaired their ability to drive IL-17A production. TGF-b blockade had no effect on the ability of DCs to drive IL-13 or IFN-g production.
IL-22 is important for development of airway inflammation and AHR after intranasal antigen challenge of mice sensitized epicutaneously
To determine the role of IL-22 in lung inflammation elicited by intranasal challenge of mice sensitized epicutaneously, we made use of Il22 2/2 mice. As previously reported, 7, 26 intranasal OVA challenge of WT mice sensitized epicutaneously with OVA elicited eosinophil and neutrophil influx into the airways, as well ously (EC) with OVA or saline and challenged intranasally with OVA are shown. Bars represent means 6 SEMs (n 5 4-7 per group). *P < .05, **P < .005, and ***P < .001. Eos, Eosinophils; Lymph, lymphocytes; Mac, macrophages; Neu, neutrophils; ns, not significant; TC, total cells.
as AHR (Fig 3, A-C) . Il22 2/2 mice sensitized epicutaneously with OVA accumulated significantly fewer total cells, eosinophils, and neutrophils in BALF and demonstrated reduced peribronchial cellular infiltrates in the lungs compared with OVA-sensitized WT controls (Fig 3, A and B) . Importantly, after intranasal OVA challenge, Il22 2/2 mice sensitized epicutaneously with OVA showed a significant decrease in airway resistance in response to methacholine compared with OVA-sensitized WT control mice (Fig 3, C) .
Lungs cells from WT mice sensitized epicutaneously with OVA secreted significantly more IL-13, IL-17A, IFN-g, IL-22, and TNF-a in response to restimulation in vitro with OVA compared with mice sensitized epicutaneously with saline. Lung cells from Il22 2/2 mice sensitized epicutaneously with OVA and subjected to airway antigen challenge secreted comparable amounts of IL-13, IL-17A, and TNF-a but significantly greater levels of IFN-g in response to OVA restimulation in vitro compared with lung cells from OVA-sensitized WT control mice (Fig 3, D) . The increased IFN-g production was selective to lung cells because we previously reported normal production of IFN-g by OVA-stimulated splenocytes of epicutaneously sensitized Il22 2/2 mice, as well as normal levels of OVA-specific IgG 2a antibody, in addition to normal production of IL-4 and IL-13 by OVA-stimulated splenocytes and normal levels of OVA-specific IgG 1 and IgE antibody. 30 The increased IFN-g production by lung cells in Il22 2/2 mice is consistent with a previous report that IL-22 downregulates T H 1 responses. 31 As expected, IL-22 secretion was not detected in lung cells from Il22 2/2 mice sensitized epicutaneously with OVA (Fig 3, D) . These results demonstrate that IL-22 plays (Fig 4, C) and neutrophils (Fig 4, D) to the antigen-challenged airways of Il22 2/2 mice sensitized epicutaneously with OVA.
Bars represent means 6 SEMs (n 5 5-7 per group). *P < .05 and **P < .005.
an important role for antigen-driven airway inflammation and AHR in mice sensitized epicutaneously after intranasal challenge.
Increased IFN-g production underlies decreased airway eosinophilia in inhalation-challenged Il22
mice sensitized epicutaneously with OVA IL-13 plays an important role in airway eosinophilia elicited by inhalation challenge in mouse models of allergic airway inflammation. 32 Furthermore, instillation of IL-13 in the airways elicits airway eosinophilia. 33 The observation that eosinophil recruitment to antigen-challenged airways was virtually absent in Il22 2/2 mice sensitized epicutaneously with OVA prompted us to examine whether IL-22 synergizes with IL-13 in driving airway eosinophilia. We first determined the dose of IL-13 that resulted in suboptimal airway eosinophilia (approximately 70% of maximum) when instilled in the airway by means of intranasal inhalation (see Fig E3, A, in this article's Online Repository at www.jacionline.org). We then examined whether addition of IL-22 enhances IL-13-driven eosinophilia. Nasal instillation of IL-22 by itself caused no airway eosinophilia (see Fig E3, B) . Coadministration of up to 1 mg of IL-22 by means of nasal instillation did not enhance IL-13-driven airway eosinophilia (see Fig E3, B) . Thus impaired eosinophilia in the antigen-challenged airways of Il22 2/2 mice sensitized epicutaneously with OVA is not due to loss of a potential synergistic effect of IL-22-on IL-13-driven airway eosinophilia.
IFN-g has been reported to inhibit the ability of IL-13 to cause airway eosinophilia. 34 We investigated whether Il22 2/2 mice sensitized epicutaneously with OVA exhibit increased Ifng mRNA levels and enhanced recruitment of IFN-g-producing cells in the lungs. Both CD3
1
CD4
1 T cells and type 1 innate lymphoid cells (ILC1s) are a source of IFN-g, 35 Ifng expression is dependent on the transcription factor T-bet encoded by Tbx21, 36 and both T H 1 cells and ILC1s are recruited to tissues by the chemokine CCL5, which binds to the chemokine receptor CXC3 expressed on these cells. 35 mRNA levels of Ifng, Tbx21, Cxcr3, and Ccl5 were increased significantly in lungs of Il22 2/2 mice sensitized epicutaneously with OVA after intranasal OVA challenge compared with their WT counterparts (Fig 4, A) . In addition, numbers of CD3 (Fig 5, B) , frequency of neutrophils in lungs (Fig 5, C) , hematoxylin and eosin (H&E)-stained lung sections (Fig 5, D) , chemokine mRNA levels in lungs (Fig 5, E) , and lung resistance in response to increasing doses of methacholine (Fig 5, F) in WT recipients of T H 22-polarized OVA-specific CD4 1 T cells from DO11.10 and DO11.10/Il22 2/2 mice after intranasal challenge with OVA. Mice that received no T cells were used as controls. Bars represent means 6 SEMs (n 5 4-6 per group). Eos, Eosinophils; Lymph, lymphocytes; Mac, macrophages; Neu, neutrophils; n.s., not significant; TC, total cells. *P < .05, **P < .005, and ***P < .001.
were increased in Il22 2/2 mice sensitized epicutaneously after intranasal OVA challenge (Fig 4, B) , suggesting that IL-22 controls recruitment of ILC1s to the lungs after intranasal challenge.
To examine whether increased IFN-g production contributed to the impaired recruitment of eosinophils to the antigenchallenged airways of Il22 2/2 mice sensitized epicutaneously with OVA, we treated the mice intranasally with neutralizing antibody to IFN-g during OVA airway challenge. Administration of anti-IFN-g antibody, but not isotype control, significantly increased airway eosinophilia after antigen inhalation in Il22 2/2 mice sensitized epicutaneously with OVA (Fig 4,  C) . This effect was specific to eosinophils because administration of IFN-g antibody did not restore neutrophil recruitment to the airways in these mice (Fig 4, D) . Reconstitution of airway eosinophilia in the challenged airways of Il22 2/2 mice sensitized epicutaneously through administration of anti-IFN-g antibody was partial because the numbers of eosinophils in the airways of these mice remained lower than in the challenged airways of WT mice sensitized epicutaneously (5.9 6 0.52 3 10 4 vs 2.04 6 0.32 3 10 5 ). These results suggest that the impaired eosinophilia in antigen-challenged airways of Il22 2/2 mice sensitized epicutaneously is in part secondary to the increased production of IFN-g in the lungs of these mice.
T H 22 antigen-specific CD4
1 T cells drive neutrophildominated airway inflammation and AHR in response to intranasal antigen challenge We next addressed the mechanisms by which lack of IL-22 impairs neutrophil recruitment into the antigen-challenged airways of mice sensitized epicutaneously. We first investigated the ability of CD4
1 T H cells that produce IL-22 to elicit airway inflammation and AHR. We examined the response to intranasal antigen challenge of WT recipients of antigen-specific CD4 1 T cells polarized in vitro into IL-22-producing cells. Naive splenic CD4
1
CD62L
1 T cells from TCR-transgenic DO11.10 mice were activated with anti-CD3 plus anti-CD28 and IL-23 in the presence of neutralizing antibodies to IL-4, IFN-g, and TGF-b, conditions known to drive the differentiation of naive CD4
1 cells into IL-22-producing cells. 27, 37 T cells polarized in vitro under these conditions are henceforth designated T H 22 cells. As expected, T H 22 cells from DO11.10 mice, but not DO11.10/Il-22 2/2 mice, secreted IL-22 (Fig 5, A) . The 2 types of cells secreted comparable levels of TNF-a and IL-13 and no detectable levels of IL-4 (Fig 5, A, and data not shown) . T H 22 cells from DO11.10/Il-22 2/2 mice secreted modestly but significantly more IL-17A and IFN-g than T H 22 cells from WT control mice (Fig 5, A) .
After antigen inhalation challenge, recipients of T H 22-polarized DO11.10 CD4 , and lung resistance in response to increasing doses of methacholine (E) in WT mice treated intranasally with saline, rIL-22, rTNF-a, or rIL-22 plus rTNF-a are shown. Bars represent means 6 SEMs (n 5 4-6 per group). Eos, Eosinophils; Lymph, lymphocytes; Mac, macrophages; Neu, neutrophils; TC, total cells. *P < .05, **P < .005, and ***P < .001.
CD4
1 T cells, exhibited a significant increase in the number of total cells and neutrophils in BALF and lung tissue (Fig 5, B and C) and increased peribronchial cellular infiltrates (Fig 5, D) compared with control mice that received no T cells. In line with the increase in neutrophil counts in the airways and lungs, recipients of T H 22-polarized DO11.10 CD4
1 T cells showed significantly increased mRNA levels of Cxcl1 and Cxcl3, but not Cxcl2, in their lungs compared with recipients of DO11.10/ Il-22 2/2 CD4 1 T cells and control mice that received no T cells (Fig 5, E) . Comparable Il17a and Ifng mRNA levels were observed in airway-challenged lungs of recipients of T H 22-polarized WT and IL-22-deficient OVA TCR-transgenic T cells (see Fig E4 in (Fig 5, F) . Together, these results demonstrate that IL-22 produced by CD4
1 T cells can drive neutrophil-dominated airway inflammation and AHR.
IL-22 synergizes with TNF-a to drive neutrophildominated airway inflammation and AHR
We investigated whether IL-22 is sufficient to drive airway inflammation and AHR. rIL-22 was administered intranasally in 2 different doses (100 and 1000 ng) daily for 3 days to WT mice. Intranasal administration of rIL-22 caused no significant increase in the number of total cells or neutrophils in BALF; no significant increase in the number of neutrophils in the lungs; no increase in peribronchial cellular infiltrates; no significant increase in mRNA levels of Cxcl1, Cxcl2, and Cxcl3 in the lungs; and no significant AHR to methacholine compared with internal administration of saline (Fig 6 and 
IL-22
1 lung cells and IL-17A and TNF-a were secreted by in vitro-polarized T H 22 cells, which, when adoptively transferred, resulted in development of neutrophil-dominated airway inflammation and AHR in response to antigen inhalation challenge, we examined whether IL-17A and TNF-a might synergize with IL-22 to drive this response. We treated WT mice intranasally with rIL-22 (1000 ng) in combination with rIL-17A (100 ng) or rTNF-a (50 ng). Mice treated with TNF-a alone exhibited a modest but significant increase in neutrophil numbers in BALF (Fig 6, A) ; no significant increase in total lung neutrophil counts (Fig 6, B) ; a minimal increase in peribronchial cellular infiltrates (Fig 6, C) ; no significant increase in Cxcl1, Cxcl2, and Cxcl3 mRNA levels in the lungs (Fig 6, D) ; and no increase in airway resistance compared with control mice treated with saline (Fig 6, E) . Importantly, mice treated with rIL-22 plus rTNF-a exhibited significantly increased numbers of total cells, neutrophils, and lymphocytes in BALF (Fig 6, A) ; increased numbers of neutrophils in the lungs (Fig 6, B) ; increased peribronchial cellular infiltrates (Fig 6, C) ; significantly increased mRNA levels of Cxcl1 and Cxcl3 in the lungs (Fig 6, D) ; and significantly enhanced airway resistance (Fig 6, E) compared to controls. There was no significant increase in Il13, Il33, Il25, or Il17a mRNA in the lungs of mice that received rIL-22 plus rTNF-a (see Fig E6 in this article's Online Repository at www.jacionline.org). Numbers of total cells, macrophages, neutrophils, and lymphocytes in BALF; numbers of neutrophils in the lungs; levels of peribronchial cellular infiltrates; mRNA levels of Cxcl1, Cxcl2, and Cxcl3 in the lungs; and airway resistance in mice treated with IL-17A alone or in combination with IL-22 were comparable with those in control mice treated with saline (see Fig E7 in this article' s Online Repository at www.jacionline.org). These results demonstrate that IL-22 synergizes with TNF-a, but not with IL-17A, to promote neutrophil airway inflammation and suggest that IL-22 and TNF-a produced by T H 22 cells synergize to drive neutrophil-dominated airway inflammation and AHR.
Blockade of TNF-a, but not IL-22, during OVA intranasal challenge decrease airway inflammation in mice epicutaneously sensitized with OVA We investigated whether blockade of IL-22 or TNF-a during intranasal challenge decreased airway inflammation in mice sensitized epicutaneously. Intranasal administration of TNF-a blocking antibody during OVA challenge caused a significant decrease in numbers of total cells, eosinophils, and neutrophils in BALF; a significant decrease in the number of neutrophils in the lungs; a decrease in levels of peribronchial cellular infiltrates; and a significant decrease in mRNA levels of Cxcl1, Cxcl2, and Cxcl3 in the lungs compared with intranasal administration of isotype control antibody (Fig 7) . Intranasal administration of IL-22 blocking antibody had no apparent effect on airway inflammation induced by intranasal OVA challenge of mice sensitized epicutaneously with OVA (Fig 7) . These results demonstrate that TNF-a plays an important role in mediating airway inflammation in response to intranasal challenge of mice sensitized epicutaneously. In contrast, although important for the induction of airway inflammation in mice challenged intranasally and sensitized epicutaneously, IL-22 plays no detectable role in the effector phase of the response to intranasal challenge (Fig 7) .
DISCUSSION
We demonstrate that IL-22 is produced by CD4 1 T cells in the lungs of mice sensitized epicutaneously and plays a critical role in airway inflammation and AHR elicited by antigen inhalation challenge of these mice. Moreover, we show that synergistic action of IL-22 with TNF-a produced by allergen-specific T H 22 cells can drive neutrophil-dominated airway inflammation.
Serum IL-22 levels, IL-22 production by antigen-stimulated splenocytes, and Il22 mRNA expression and IL-22 production in the lungs after intranasal antigen challenge all increased in WT mice sensitized epicutaneously with OVA. Epicutaneous sensitization preferentially elicited an IL-22 response compared with intraperitoneal immunization. We previously showed that epicutaneous sensitization with OVA also preferentially elicits an IL-17A response compared with evidence of increased serum IL-17A levels, IL-17A production by antigen-stimulated splenocytes, and Il17a mRNA expression and IL-17A production in the lungs after intranasal antigen challenge. 7 Induction of both IL-22 and IL-17A after epicutaneous sensitization is consistent with the observation that the 2 cytokines are often produced by overlapping populations of T H cells that require different factors for their induction. 27 Previously, we demonstrated that IL-22 production and, to a lesser extent, IL-17A production after epicutaneous sensitization is dependent on IL-23, a cytokine critical for induction of IL-22-producing CD4
1 T H cells.
30
Although TGF-b is important for IL-17A induction after epicutaneous sensitization, 7 it had no detectable role in IL-22 induction in epicutaneously sensitized mice. We also showed that IL-23 is primarily induced in and released by keratinocytes after tape stripping, which is used for epicutaneous sensitization. 30 Il23 mRNA expression and IL-23 production are also induced in normal human skin subjected to mechanical injury by tape stripping. 30 Furthermore, Il23 mRNA expression is increased in the skin of patients with AD. 38 Together, these findings suggest that our examination of the role of IL-22 in airway inflammation elicited by antigen inhalation in epicutaneously sensitized mice is relevant to asthma that develops in patients with AD.
Our results demonstrate that IL-22 plays a proinflammatory role in airway inflammation in epicutaneously sensitized mice.
Il22
2/2 mice sensitized epicutaneously with OVA exhibited decreased eosinophil and neutrophil and influx in the BALF, attenuated lung inflammation, and diminished AHR after intranasal challenge. In line with these results, previous reports have been shown that IL-22 deficiency or blockade by antibody reduces airway inflammation in mice sensitized subcutaneously with OVA 17 or mice treated intratracheally with a high dose of bleomycin. 39 In contrast, several reports indicate a protective role of IL-22 in the lungs of intraperitoneally sensitized mice because intraperitoneally sensitized Il22 2/2 mice exhibited enhanced airway inflammation after inhalation challenge and intranasal instillation of rIL-22. These results suggest that the route of allergen sensitization might determine whether IL-22 plays a pathogenic role or a protective role in airway inflammation elicited by antigen inhalation.
Deficiency of IL-22 increased the expression of Ifng and its transcriptional regulator, Tbx21, as well as of the chemokine Ccl5 and its receptor, Cxcr3, expressed by T H 1 cells and ILC1s in lungs of mice sensitized epicutaneously with OVA and challenged intranasally with antigen. It also increased, the number of IFN-g-producing lung ILCs and IFN-g production by OVAstimulated lung cells in these mice. These results suggest that IL-22 inhibits local IFN-g production during antigen-driven airway inflammation. IL-22 production in BALF of asthmatic patients inversely correlates with IFN-g-regulated proinflammatory mediators. 23 Furthermore, IL-22 blockade 40 or selective ablation in CD4
1 T cells of Ahr, a transcription factor required for T H 22 polarization, 31 increases the number of T H 1 cells in a model of collagen-induced arthritis. 41 IFN-g inhibits airway eosinophilia by counteracting the effects of IL-4 and IL-13. 42 Importantly, IFN-g blockade was restored in part in airway eosinophilia in the antigen-challenged lungs of Il22 2/2 mice sensitized epicutaneously with OVA. This suggests that IL-22 promotes airway eosinophilia in our model by inhibiting local production of IFN-g. Partial restoration of airway eosinophilia in the antigenchallenged airways of Il22 2/2 mice sensitized epicutaneously Ab, Antibody; Eos, eosinophils; Lymph, lymphocytes; Mac, macrophages; Neu, neutrophils; ns, not significant; TC, total cells. *P < .05, **P < .005, and ***P < .001.
by IFN-g blockade suggests the presence of additional mechanisms by which IL-22 promotes eosinophil recruitment. CD4 1 T cells are the major source of IL-22 during airway inflammation. 36 We demonstrated that IL-22 was expressed in CD4 49 and Candida albicans 46 infections and is thought to be important in driving tissue inflammation in patients with scleroderma 44 and Behçet disease. 48 In contrast, intranasal installation of IL-22 together with IL-17A, another cytokine expressed by T H 22 cells, had no detectable effect, although IL22 and IL-17A have been reported to synergize to promote airway inflammation 39 and in inducing the production of antimicrobial peptides by keratinocytes. 43 Given the normal production of TNF-a and IL-17A by lung cells from airwaychallenged and epicutaneously sensitized Il22 2/2 mice, our data suggest that loss of IL-22 synergy with TNF-a contributed to defective recruitment of neutrophils into the airways of Il22 2/2 mice. Consistent with the results obtained in the subcutaneous immunization model, 17 IL-22 blockade before inhaled antigen challenge had no effect on airway inflammation, whereas TNFa blockade inhibited it. This suggests that although IL-22 is important in eliciting an immune response that promotes airway inflammation, it is not important in the effector phase of the response. Thus IL-22 blockade could be beneficial during priming of the response to epicutaneous sensitization, whereas TNF-a blockade could be beneficial in protecting from inhaled antigen challenge subsequent to epicutaneous sensitization.
In summary, our results suggest that cutaneous sensitization through mechanically injured skin, as occurs in patients with AD, elicits antigen-specific T H 22 cells that produce IL-22 and TNF-a in response to allergen exposure through the airways and thereby promote eosinophil-and neutrophil-mediated lung inflammation and AHR. Our findings suggest that blockade of IL-22 might be beneficial in prevention of allergic asthma in patients with AD.
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